Emergent BioSolutions (EBS) Tops Q2 EPS by 18c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $2.04 +9.68%
EPS Growth %: +73.8%
Financial Fact:
Cost of product sales: 39.56M
Today's EPS Names:
MAXN, CSTR, ACU, More
EPS Growth %: +73.8%
Financial Fact:
Cost of product sales: 39.56M
Today's EPS Names:
MAXN, CSTR, ACU, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of $0.36, $0.18 better than the analyst estimate of $0.18. Revenue for the quarter came in at $126.1 million versus the consensus estimate of $114.25 million.
Emergent BioSolutions reaffirmed FY2015 guidance.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Schlumberger (SLB) earnings in-line, revenue beats expectations
- BancFirst Corp. (BANF) Tops Q1 EPS by 11c
- Acme United (ACU) Misses Q1 EPS by 20c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
